Kirby Institute
kirby.unsw.edu.auTotal trials
92
Active
14
Phase 3
14
Total enrollment
244,188
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 10 of 10 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Moxidectin | — | — | — | — | — | 1 | |
| Ivermectin | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Pitavastatin 4 Mg Oral | — | — | — | — | — | 1 | |
| Rosuvastatin and Ezetimibe | — | — | — | — | — | 1 | |
| diphtheria and tetanus toxoids (adsorbed) vaccine | — | — | — | — | — | 1 | |
| COVID-19 vaccine | — | — | — | — | — | 1 | |
| 4CMenB vaccine | — | — | — | — | — | 1 | |
| 12 weeks of weekly subcutaneous semaglutide | — | — | — | — | — | 1 | |
| Oritavancin | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2026-07
- 2026-12-31
- 2027-01
- 2028-06-30
- 2029-03-31
Top conditions
- Hepatitis C19
- HIV Infections16
- HIV10
- Hepatitis C, Chronic9
- HIV Infection6
- Hepatitis B5
- Cardiovascular Disease4
- Pandemic Influenza3
Frequently asked questions about Kirby Institute
- How many clinical trials does Kirby Institute have on ClinicalTrials.gov?
- Kirby Institute is listed as the lead sponsor on 92 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Kirby Institute's trials are in Phase 3?
- 14 of Kirby Institute's trials are in Phase 3, spread across 10 active drug programs.
- What therapeutic areas does Kirby Institute focus on?
- Kirby Institute's most-studied conditions on ClinicalTrials.gov are Hepatitis C, HIV Infections, HIV, Hepatitis C, Chronic, HIV Infection.
- When are Kirby Institute's next clinical trial readouts?
- Kirby Institute has 6 upcoming primary-completion readouts tracked here; the soonest is “Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men”, expected around 2025-06-30.